Loading
Carter Cliff

Carter Cliff

CEO, Papillon Therapeutics, Inc.
United States
Carter Cliff is CEO of Papillon Therapeutics. As co-founder and executive, he has raised $125 million for biotechnology companies developing cell and gene-modified cell therapies, including Opsis Therapeutics, Vascugen, and Ryne-Bio. BlueRock Therapeutics (a Bayer AG company) entered a Strategic R&D Alliance with Opsis, providing Opsis with a $70 million up-front commitment for option of three induced pluripotent stem cell (iPSC) retinal cell therapy programs. Carter previously spearheaded and oversaw development of a portfolio of iPSC therapeutics at FUJIFILM Cellular Dynamics Inc. (FCDI).
Sessions

BIO DOUBLE HELIX SPONSOR

Our sponsors help support BIO's mission to support and advocate for the biotechnology industry.

Loading

BIO HELIX SPONSORS